// App-Quantinova.ai

: Bimekizumab response maintenance in high-impact areas in patients with moderate to severe plaque psoriasis: Pooled results through 96 weeks of the BE SURE, BE READY, and BE RADIANT phase 3/3b trials

Researchers

Presenter

  • Joseph F. Merola

Principal Investigators

  • Richard B. Warren

  • George Han

  • Andreas Pinter

  • Luke Peterson

  • Veerle Vanvoorden

  • Nancy Cross

  • Natalie Nunez Gomez

  • Diamant Thaçi

Medical Centers

  • Harvard Medical School, Brigham and Women's Hospital, Boston, MA.

  • The Dermatology Centre, Salford Royal NHS Foundations Trust, Manchester NIHR Biomedical Research Centre, The University of Manchester, University of Manchester, Manchester, UK

  • Department of Otolaryngology, Mount Sinai Medical Center, New York, NY

  • University Hospital Frankfurt, Frankfurt, Germany

  • UCB Pharma, Raleigh, NC

  • UCB Pharma, Monheim, Germany

  • Comprehensive Center for Inflammation Medicine, University of Lubeck, Lubeck, Germany

Locations

  • United States

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriasis

Biomarkers

  • N/A

Drug/Treatment

  • bimekizumab

Outcome

  • N/A

Study Design

  • Open Label

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved